Inventiva stock breaks through €3.38 and surges 4.5% during trading session
The Burgundy biotech specializing in fibrotic and metabolic diseases enjoys a sharp rebound in mid-morning trading. The stock ranks among the strongest gainers on the SBF 120, while the Paris index remains flat.
A breakthrough at €3.38 that places the stock above its short-term averages
Inventiva stock gains 4.58% to €3.43 during the session. It has broken upward through its 30-day high (€3.38), which now acts as support, and is holding above this level. This movement extends a gain of 18.1% over seven days and 20.4% over one month, which only partially offset the 12.6% decline over three months.
The stock is trading 15.3% above its 20-day moving average and 1.9% above its 50-day moving average, while the 200-day MA (€4.19) remains 18.3% above the current price. The SBF 120 declines by 0.02%.
Treasury of €166.1 million following half-year results published on July 29
The rebound occurs within a context of strengthened financing. The cash position of the Daix-based biotech reaches €166.1 million as of June 30, 2026, following a €103 million capital offering and a €75 million financing operation announced on June 2.
Upon publication of H1 2026 results on July 29, the company reported near-zero revenue (€0.02) for the half-year, compared to €4.5 million one year earlier. It indicated a cash runway limited to the end of the second quarter 2027 without additional financing.
The primary results of the NATiV3 phase 3 study remain the key focus for this stock. The analyst consensus can be found on the analyst opinions page for Inventiva.
